Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finnish population

Neuroscience Letters

Volumn 367, Issue 2, 2004, Pages 168-170

  Clarimon, Jordi ^a   Eerola, Johanna ^b   Hellström, Olli ^c   Tienari, Pentti J ^b   Singleton, Andrew ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

Author keywords

Complex disorder; Finland; Genetic association; Parkinson's disease; Polymorphism; PON1

Indexed keywords

ARYLDIALKYLPHOSPHATASE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; FINLAND; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POPULATION; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ARGININE; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; FINLAND; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTAMINE; HUMANS; LEUCINE; MALE; METHIONINE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC;

EID: 4344624315     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2004.05.108     Document Type: Article

References (21)

1. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52:1993;598-608
2. Akhmedova S.N., Yakimovsky A.K., Schwartz E.I. Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J. Neurol. Sci. 184:2001;179-182
3. Allebrandt K.V., Souza R.L., Chautard-Freire-Maia E.A. Variability of the paraoxonase gene (PON1) in Euro- and Afro-Brazilians. Toxicol. Appl. Pharmacol. 180:2002;151-156
4. Brophy V.H., Jarvik G.P., Richter R.J., Rozek L.S., Schellenberg G.D., Furlong C.E. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics. 10:2000;453-460
5. Carmine A., Buervenich S., Sydow O., Anvret M., Olson L. Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Mov. Disord. 17:2002;764-766
6. Cowan J., Sinton C.M., Varley A.W., Wians F.H., Haley R.W., Munford R.S. Gene therapy to prevent organophosphate intoxication. Toxicol. Appl. Pharmacol. 173:2001;1-6
7. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14:1996;334-336
8. de Rijk M.C., Tzourio C., Breteler M.M., Dartigues J.F., Amaducci L., Lopez-Pousa S., Manubens-Bertran J.M., Alperovitch A., Rocca W.A. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 62:1997;10-15
9. Gentry P.R., Hack C.E., Haber L., Maier A., Clewell H.J. III An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. Toxicol. Sci. 70:2002;120-139
10. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry. 55:1992;181-184
11. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3:1993;73-76
12. Kelada S.N., Costa-Mallen P., Checkoway H., Viernes H.A., Farin F.M., Smith-Weller T., Franklin G.M., Costa L.G., Longstreth W.T. Jr., Furlong C.E., Jarvik G.P., Swanson P.D. Paraoxonase 1 promoter and coding region polymorphisms in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 74:2003;546-547
13. Kondo I., Yamamoto M. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res. 806:1998;271-273
14. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980
15. Le Couteur D.G., McLean A.J., Taylor M.C., Woodham B.L., Board P.G. Pesticides and Parkinson's disease. Biomed. Pharmacother. 53:1999;122-130
16. Mackness B., Mackness M.I., Arrol S., Turkie W., Julier K., Abuasha B., Miller J.E., Boulton A.J., Durrington P.N. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 139:1998;341-349
17. Marder K., Levy G., Louis E.D., Mejia-Santana H., Cote L., Andrews H., Harris J., Waters C., Ford B., Frucht S., Fahn S., Ottman R. Familial aggregation of early- and late-onset Parkinson's disease. Ann. Neurol. 54:2003;507-513
18. Moilanen J.S., Autere J.M., Myllyla V.V., Majamaa K. Complex segregation analysis of Parkinson's disease in the Finnish population. Hum. Genet. 108:2001;184-189
19. Sajantila A., Salem A.H., Savolainen P., Bauer K., Gierig C., Paabo S. Paternal and maternal DNA lineages reveal a bottleneck in the founding of the Finnish population. Proc. Natl. Acad. Sci. U.S.A. 93:1996;12035-12039
20. S. Schneider, J. Kueffer, D. Roessli, L. Excoffier, Arlequin ver.2000: a software environment for the analysis of population genetics data, 2000.
21. Wang J., Liu Z. No association between paraoxonase 1 (PON1) gene polymorphisms and susceptibility to Parkinson's disease in a Chinese population. Mov. Disord. 15:2000;1265-1267